CNS Market Research

A concise collection of reports on CNS, data includes Drug Discoveries, Disorders, Prospects and Opportunities.

Stay up-to-date with new products added to this category

Results 1 - 31 of 31

previous 1 next

Title	Date	Price
The Global Multiple Sclerosis Market 2009-2024	Mar 2009	£1,499
Neurodegenerative Market Forecast to 2013	Feb 2009	£6,185
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders	Dec 2008	£2,285
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies	Nov 2008	£8,070
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail	Nov 2008	£4,635
The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities	Sep 2008	£2,340
CNS Drug Discoveries: Depression	Aug 2008	£595
CNS Drug Discoveries: what the future holds 2008 FULL REPORT	Aug 2008	£1,795
CNS Drug Discoveries: Multiple Sclerosis	Aug 2008	£595
CNS Therapeutics	May 2008	£2,410
CNS Generic Drugs: Prospects and Opportunities to 2012	Apr 2008	£995
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors	Apr 2008	£8,070
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022	Oct 2007	£1,499
The CNS Market Outlook To 2012	Oct 2007	£1,755
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed	Sep 2007	£7,600
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market	Sep 2007	£6,000
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits	Sep 2007	£7,600
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack	Sep 2007	£7,600
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities	Jun 2007	£995
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007	Jun 2007	£1,999
Pipeline Insight: Depression Novel drugs to grow third-line market	Mar 2007	£6,950
Innovations in CNS Novel therapeutics and future R&D strategies	Jan 2007	£1,755
Stakeholder Insight: Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice	Dec 2006	£8,070
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines	Dec 2006	£8,070
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries	Dec 2006	£6,950
CNS Drug Discoveries: Neurodegenerative Disorders	Nov 2006	£795
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)	Nov 2006	£795
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share	Nov 2006	£6,950
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors	Oct 2006	£6,950
Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area	Dec 2005	£795
Forecast Insight: Depression Generic induced brand erosion leads to market decline	Nov 1999	£8,070